Parenterally administered
Shenmai has the functions of benefiting vital energy, nourishing Yin, generating body fluids, and activating the pulse. Modern pharmacological studies have shown that constituents of parenterally administered
Shenmai such as
ginsenosides and ophiopogonin can improve
hypoxia tolerance, immunity, function, and microcirculation of the heart, and
free radical scavenging. Therefore, parenterally administered
Shenmai is a suitable treatment for
shock. Literature review and analysis of HIS data outcomes, are the two methods used to study the type of
shock treated, dose and combinations of other medications used with parenterally administered
Shenmai. The results of the two methods are consistent in understanding the clinical features of shock therapy with parenterally administered
Shenmai which thereby provides information for the design of prospective studies. However, the results of the two methods are limited by the poor quality of the literature and the low level of evidence for clinical evaluation after the registration of
Shenmai. Nevertheless, HIS data provides retrospective data although some information is missing. Thus, although the results of the two methods can be used as the foundation to support the clinical evaluation of post-marketing parenterally administered
Shenmai, final conclusions can only be drawn based on prospective studies.